tbuckley/cabot-search huggingface dataset:
Induction of Labor Compared with Expectant Management for Prelabor Rupture of the Membranes at Term
Authors: Mary E. Hannah, Arne Ohlsson, Dan Farine, Sheila A. Hewson, Ellen D. Hodnett, Terri L. Myhr, Elaine E.L. Wang, Julie A. Weston, Andrew R. Willan
Journal: New England Journal of Medicine (1996)

As the interval between rupture of the fetal membranes at term and delivery increases, so may the risk of fetal and maternal infection. It is not known whether inducing labor will reduce this risk or whether one method of induction is better then another.We studied 5041 women with prelabor rupture of the membranes at term. The women were randomly assigned to induction of labor with intravenous oxytocin; induction of labor with vaginal prostaglandin E2 gel; or expectant management for up to four days, with labor induced with either intravenous oxytocin or vaginal prostaglandin E2 gel if complications developed. The primary outcome was neonatal infection. Secondary outcomes were the need for cesarean section and women's evaluations of their treatment.The rates of neonatal infection and cesarean section were not significantly different among the study groups. The rates of neonatal infection were 2.0 percent for the induction-with-oxytocin group, 3.0 percent for the induction-with-prostaglandin group, 2.8 percent for the expectant-management (oxytocin) group, and 2.7 percent for the expectant-management (prostaglandin) group. The rates of cesarean section ranged from 9.6 to 10.9 percent. Clinical chorioamnionitis was less likely to develop in the women in the induction-with-oxytocin group than in those in the expectant-management (oxytocin) group (4.0 percent vs. 8.6 percent, P<0.001), as was postpartum fever (1.9 percent vs. 3.6 percent, P=0.008). Women in the induction groups were less likely to say they liked "nothing" about their treatment than those in the expectant-management groups.In women with prelabor rupture of the membranes at term, induction of labor with oxytocin or prostaglandin E2 and expectant management result in similar rates of neonatal infection and cesarean section. Induction of labor with intravenous oxytocin results in a lower risk of maternal infection than does expectant management. Women view induction of labor more positively than expectant management.
The Framework of Health Care Reform
Authors: P Starr
Journal: New England Journal of Medicine (1993)

President Clinton's Health Security plan is a distinctively American synthesis. Like universal health insurance in other industrialized countries, it covers a comprehensive set of benefits for all citizens and makes health coverage a right of citizenship. But unlike most systems abroad, it offers consumers the opportunity to choose among private health plans. Like programs abroad, the Health Security plan establishes national limits on the growth of health costs for covered benefits. It places a distinctive emphasis, however, on helping consumers obtain value for money by requiring health plans to compete for enrollment on the basis of both price and service. . . .
Case 11-2015
Authors: Farrin A. Manian, Diana Alame
Journal: New England Journal of Medicine (2015)

A 28-year-old woman was seen in the emergency department of this hospital because of the acute onset of headache, fever, rash, and myalgias. On examination, she had petechiae on the chest, abdomen, and thighs and a purpuric lesion on the right shoulder.
Endomicroscopie confocale appliquée aux voies biliaires: étude bicentrique comparant les biopsies optiques à l'histologie chez 46 patients
Authors: F Caillol, C Duburque, G Monges, P Gosset, E Bories, C Pesenti, B Filoche, M Giovannini
Journal: Endoscopy (2011)

Introduction: L'endomicroscopie confocale est une technique émergente permettant la réalisation de véritables biopsies optiques au niveau du tube digestif. Le but de cette étude de phase 2 est l'évaluation des biopsies optiques des voies biliaires avec les prélèvements histologiques endobiliaires et le résultat histologique définitif. Nous rapportons ici notre expérience bicentriques.
A Phase I–II Trial of Multiple-Dose Polyriboinosinic-Polyribocytidylic Acid in Patients With Leukemia or Solid Tumors
Authors: Richard A. Robinson, Vincent T. DeVita, Hilton B. Levy, Samuel Baron, Susan P. Hubbard, Arthur S. Levine
Journal: JNCI Journal of the National Cancer Institute (1976)

Polyriboinosinic-polyribocytidylic acid (poly I - poly C), an interferon inducer, was administered in multiple doses of 0.3-75 mg/m2 to 26 patients with a variety of solid tumors, 9 with acute leukemia, and 2 with chronic myelogenous leukemia in blast crisis. Forty-four separate drug trials were comprised of various schedules and routes of administration. Toxic reactions included fever (in 66% of the trials), transient elevation of serum glutamic-oxaloacetic transaminase and serum glutamic-pyruvic transaminase (25%), minimal laboratory evidence of coagulation abnormalities (59%), and hypersensitivity (5%). These toxic manifestations did not relate to dose level or magnitude of interferon induction. Poly I - poly C administered iv induced low serum concentrations of interferon in 24/38 trials (63%), but the correlation between drug dose and peak interferon titer was not linear. Poly I - poly C administered iv or im was not effective as an inducer of interferon in the cerebrospinal fluid. Similarly, poly I - poly C administered im or by inhalation did not produce detectable serum levels of interferon. No patients experienced an objective tumor response to the administration of poly I - poly C, and most (76%) had progression of their disease while receiving the drug.
Methemoglobinemia Risk Factors: Response to Avery and L'hirondel
Authors: Catherine Zeman, Burton Kross, Mariana Vlad
Journal: Environmental Health Perspectives (2003)

The article by Knap et al., “Indicators ofOcean Health and Human Health:Developing a Research and MonitoringFramework” (Knap et al. 2002), was awelcome overview of issues that link theenvironmental condition of marine/oceanecosystems and human disease. The comple-ment to the growing concern about theconnection between health and the marineenvironment is a corresponding emphasison large freshwater lake ecosystems andhuman health.In the United States and Canada, forexample, the Great Lakes basin contains a setof inland seas that are oceanographic in scale.They serve as a highway for internationalmaritime commerce and support a $1 bil-lion/year recreational and commercial fishingindustry. In addition, they must also supplydrinking water for over 15 million people. The Great Lakes hold about 20% of theworld’s surface freshwater. In this context,the degradation of the Great Lakes ecosys-tem through chemical and biological conta-mination presents an enormous challenge forthe future. Questions about the impact ofmethyl mercury, polychlorinated biphenyls,and other chemicals on the health of thosewho eat fish from the Great Lakes; about therole of bacterial loading of coastline beacheson disease; and about the quality of drinkingwater taken from the lakes are among thosein need of intense study. Surprisingly, in comparison with thenumber of research organizations and fund-ing opportunities that concentrate on themarine environment, there are very fewgovernmental or academic programs thattarget the Great Lakes environment. In thiscontext, it should be a priority to developresearch programs that can enlarge theknowledge base so that the Great Lakes canbe sustained as the centerpiece of our fresh-water resources.
Abstract 5037: Identifying differentially expressed microRNAs in retinoblastoma
Authors: Joshua Martin, Paul Bryar, Marilyn Mets, Joanna Weinstein, Elio F. Vanin, Fabricio F. Costa, Marcelo B. Soares, Nikia A. Laurie
Journal: Cancer Research (2012)

Abstract Retinoblastoma, the most common pediatric cancer of the eye, is a devastating and sometimes fatal pediatric cancer. Within the United States, the majority of retinoblastoma patients are diagnosed before their 2nd birthday, and many lose their sight due to this disease. Approximately 75% of the retinoblastoma patients in the United States have unilateral disease, and treatment for many unilateral patients with advanced disease involves enucleation (removal of the eye). Therefore, new more effective targeted therapies for retinoblastoma could save a child's quality of life by preserving their sight. Outside of the United States, advanced retinoblastoma is an even greater clinical challenge in low-income countries, where the mortality rate among children diagnosed with advanced retinoblastoma is as high as 70%. Currently, the chemotherapeutic treatments for retinoblastoma involve the use of broad-based drugs. However, therapies targeted directly to aberrant signaling pathways may provide more effective therapy for this disease. MicroRNAs, short noncoding RNA transcripts that can regulate the expression of target genes, are known to affect the progression of many different tumor types. MicroRNAs (miRNAs) are also ideal therapeutic targets because they are amenable to therapeutic manipulation. To identify miRNAs associated with retinoblastoma progression, we have conducted miRNA profiling studies on 12 late-stage human retinoblastoma tumors. Our analysis has led to the identification of 19 differentially expressed miRNAs (p&amp;lt;0.05) in retinoblastoma as compared to normal human retina. From those 19 miRNAs, 15 miRNAs are newly associated as being differentially expressed in retinoblastoma. These miRNAs could serve as potential therapeutic targets for retinoblastoma due to their known involvement in viability, proliferation, cell cycle regulation, and apoptosis in other tumor types. This is an essential step in the discovery of miRNAs associated with retinoblastoma progression, and in the identification of potential therapeutic targets for this disease. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 5037. doi:1538-7445.AM2012-5037
Abstract 1556: Immunological naturalization of immunocompetent host mice to luciferase-GFP for consistent tracking of transplanted tumors.
Authors: Chi-Ping Day, Zoe Weaver, John Carter, Carrie Bonomi, Terry Van Dyke, Melinda Hollingshead, Glenn Merlino
Journal: Cancer Research (2013)

Abstract Optical imaging of labeled cells is the most prevailing method for cell tracking in mouse models. However, the immunogenicity of xenobiotic reporter genes, such as the commonly used firefly luciferase (ffLuc) and enhanced green fluorescence protein (eGFP), results in inconsistency in cell labeling and tumor progression, preventing their use in host mice with normal immunity. To resolve this issue, we have generated a reporter gene-tolerized transgenic mouse in which an ffLuc-eGFP fusion gene was targeted to the anterior pituitary gland using a rat Growth Hormone promoter (dubbed the “glowing-head” mouse). When ffLuc-eGFP-labeled Lewis Lung Carcinoma (LLC) tissue was subcutaneously transplanted into syngeneic glowing-head mice (GH-c-brd), their non-transgenic litter-mates (WT-c-brd), and immunocompromised Nod-Scid (balb/c) mice, anti-GFP antibody was induced only in the circulation of WT-c-brd. Labeled LLC also exhibited fewer CD4+ T cells but more macrophages in GH-c-brd than in WT-c-brd, suggesting it induced adaptive immunity in the latter. Moreover, GH-c-brd exhibited faster subcutaneous tumor growth and post-resection metastatic progression, and maintained more consistent tumor labeling, as compared to WT-c-brd and even Nod-Scid mice. Interestingly, in an adjuvant chemotherapeutic setting, the immunogenicity of the labeled tumor was able to deter metastatic progression in a manner similar to that obtained by drug treatment. We conclude that the immunogenicity of xenobiotic labeling markers can significantly influence disease progression and therapeutic responses thereby compromising immunocompetent preclinical cancer models, and that the glowing-head mouse can be used to circumvent such problems and promote consistent disease monitoring. Citation Format: Chi-Ping Day, Zoe Weaver, John Carter, Carrie Bonomi, Terry Van Dyke, Melinda Hollingshead, Glenn Merlino. Immunological naturalization of immunocompetent host mice to luciferase-GFP for consistent tracking of transplanted tumors. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 1556. doi:10.1158/1538-7445.AM2013-1556
Stat Bite: Autologous Bone Marrow Transplates for Cancer, 1989-1993
Authors: M. M. Horowitz
Journal: JNCI Journal of the National Cancer Institute (1994)

Journal Article Stat Bite: Autologous Bone Marrow Transplates for Cancer, 1989–1993 Get access Mary M. Horowitz, M.D. Mary M. Horowitz, M.D. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 86, Issue 14, 20 July 1994, Page 1045, https://doi.org/10.1093/jnci/86.14.1045 Published: 20 July 1994
Tc-99m Labeled Antigranulocyte Monoclonal Antibody Imaging for the Detection of an Abdominal Abscess
Authors: GERHARD GÖRRES
Journal: Clinical Nuclear Medicine (1997)

The most widely used agents for the detection of pathology in undiagnosed fever are Ga-67, labeled white cells, and human polyclonal immunoglobulin G (HIG). The high uptake in normal bone marrow may limit the use of Tc-99m labeled antigranulocyte monoclonal antibodies(Tc-99m MoAb) for the detection of infection in the thorax and abdomen. However, the advantage of Tc-99m MoAb is the simplicity of its use compared with techniques that require the isolation of autologous white blood cells. Although Tc-99m has a short half-life of 6 hours, delayed images can be obtained with sufficient image quality. The findings of Tc-99m MoAb scintigraphy in an immunocompromised patient are described.
PET-CT Surveillance versus Neck Dissection in Advanced Head and Neck Cancer
Authors: Hisham Mehanna, Wai-Lup Wong, Christopher C. McConkey, Joy K. Rahman, Max Robinson, Andrew G.J. Hartley, Christopher Nutting, Ned Powell, Hoda Al-Booz, Martin Robinson, Elizabeth Junor, Mohammed Rizwanullah, Sandra V. von Zeidler, Hulya Wieshmann, Claire Hulme, Alison F. Smith, Peter Hall, Janet Dunn
Journal: New England Journal of Medicine (2016)

The role of image-guided surveillance as compared with planned neck dissection in the treatment of patients with squamous-cell carcinoma of the head and neck who have advanced nodal disease (stage N2 or N3) and who have received chemoradiotherapy for primary treatment is a matter of debate.
FRI0150 Maintenance of remission in rheumatoid arthritis patients with low-moderate disease activity following withdrawal of certolizumab PEGOL treatment: Week 52 results from the certain study
Authors: J.S. Smolen, P. Emery, G. Ferraccioli, W. Samborski, F. Berenbaum, O. Davies, W. Koetse, B. Bennett, H. Burkhardt
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Certolizumab pegol (CZP) increased rates of remission and low disease activity (LDA) as an addition to non-biologic DMARDs in rheumatoid arthritis (RA) patients (pts) with long-standing, low/moderate disease activity (DA).<sup>1</sup> <h3>Objectives</h3> To evaluate the maintenance of remission to week (Wk) 52 in pts with low/moderate DA following treatment (tx) withdrawal after 24Wks of CZP or placebo (PBO). <h3>Methods</h3> CERTAIN, a double-blind (DB), randomized, Phase IIIb study, enrolled pts with low to moderate DA (CDAI &gt;6 and ≤16) (NCT00674362). Following 24Wks DB phase (CZP 400mg/PBO at Wks 0, 2, 4, then CZP 200mg/PBO every 2 Wks [Q2W]) pts in CDAI remission (≤2.8) at both Wks 20 and 24 stopped randomized tx but remained on conventional DMARDs; remitters who flared between Wk24 and Wk52 were retreated with CZP. Pts not in remission who withdrew at Wk24 entered an open-label extension. Primary endpoint was CDAI remission at both Wks 20 and 24 (NRI). Secondary endpoints included maintenance of CDAI remission when randomized tx was stopped. <h3>Results</h3> Baseline (BL) characteristics (means) were similar for CZP (n=96) vs. PBO (n=98) pts. A greater proportion of CZP pts than PBO pts were in LDA or remission at Wk12 and Wk24 (Fig.A). Over 3 times as many CZP pts had CDAI remission at both Wks 20 and 24 vs. PBO (18.8% vs. 6.1%, p&lt;0.05).<sup>1</sup> Lower HAQ and pain scores at BL were associated with improved CDAI DA status at Wk24 for CZP and PBO. At Wk24, 18 prior CZP (1 pt withdrew before the first efficacy measurement) and 6 prior PBO pts stopped therapy. CDAI remission was retained up to Wk52 in 3/17 prior CZP vs. 2/6 prior PBO pts, with 7/17 vs. 2/6 pts in CDAI remission/LDA at Wk52. SDAI remission was observed in 4/17 prior CZP vs. 2/6 prior PBO pts, and DAS28(ESR) remission in 4/17 pts vs. 1/6 pt. Median time to loss of CDAI remission (all pts) was 42.5 days (Fig.B). <h3>Conclusions</h3> In RA pts with long-standing low/moderate DA, addition of CZP to non-biologic DMARDs increased rates of remission and LDA and inhibited progression to high DA. On stopping CZP therapy, most pts were unable to maintain remission, which may have implications for stopping TNF inhibitor therapy in this pt population. <h3>References</h3> Smolen et al. Ann Rheum Dis 2011;70(Suppl3):25 <h3>Disclosure of Interest</h3> J. Smolen Grant/Research support from: UCB Pharma, Consultant for: UCB Pharma, P. Emery Grant/Research support from: UCB Pharma, Consultant for: UCB Pharma, G. Ferraccioli: None Declared, W. Samborski Consultant for: UCB Pharma, F. Berenbaum Consultant for: UCB Pharma, O. Davies Employee of: UCB Pharma, W. Koetse Employee of: UCB Pharma, B. Bennett Shareholder of: UCB Pharma, H. Burkhardt Consultant for: UCB Pharma
Surgeons Call for Independence From U.S. Food and Drug Administration
Authors: C. Vanchieri
Journal: JNCI Journal of the National Cancer Institute (1993)

Journal Article Surgeons Call for Independence From U.S. Food and Drug Administration Get access Cori Vanchieri Cori Vanchieri Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 85, Issue 5, 3 March 1993, Pages 353–354, https://doi.org/10.1093/jnci/85.5.353 Published: 03 March 1993
FRI0151 Correlations between Sleep Disturbance and Specific Disease Parameters in Ankylosing Spondylitis: Table 1.
Authors: W. Hamdi, I. Cherif, I. Zouch, D. Kaffel, M.M. Kchir
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Sleep disturbance is a frequent feature of chronic inflammatory rheumatisms particularly in Ankylosing Spondylitis (AS). <h3>Objectives</h3> The aim of this study was to evaluate sleep quality and its relationship with specific disease parameters in patients with AS. <h3>Methods</h3> We conduct a cross sectional prospective study including patients with AS fulfilling the New York modified criteria. The MOS sleep Questionnaire was used for the assessment of sleep disturbance. It is a 12-item questionnaire exploring 6 domains of sleep: sleep adequacy, sleep disturbance, sleep quantity, daytime sleepiness, snoring and shortness of breath or headache. It leads to two sleep problem indexes (SP1 and SP2). Pain was evaluated by VAS. Disease activity was evaluated by BASDAI, ASDAS ESR and ASDAS CRP, functional impairment and quality of life by ASQOL and BASFI and structural damage by BASRI and mSASS. <h3>Results</h3> Fifty patients with AS patients were included. The mean age was 42±12,1 years (range 18 to 65) with a male to female ratio about 3,5. The mean body mass index (BMI) was 24,8±4,1 kg/m<sup>2</sup>. The mean disease duration was 9,8±8,1years [range 0,5 to 39]. The mean duration of morning stiffness was 36±35 minutes [range 0to 120] and the mean awakening number was 1,52±1,44 times per night. The mean VAS pain was 49,85±25,17 [range 0,5 to 90]. The mean BASDAI was 47±24,56 [range 0 to 100]. The mean ASDASESR was 3±1,14 [range 1 to 5,1] and the mean ASDASCRP was 2,9±1,03 [range 1to 5]. The mean BASFI was 48,3±29,8 [range 0 to 98]. The mean ASQOL was 4,7±5,38 [range to]. The mean BASRI was 7,5±3,27. The mean m SASSS was 10,52±13,38. The mean ESR was 34,9±21,9 [4-84] and the mean CRP was 18,9±17 [3-73]. The results of the MOS sleep questionnaire and the correlations of its different items with disease specific parameters are presented in Table 1. <h3>Conclusions</h3> Our study showed that the poor sleep quality in AS is especially associated with disease activity, pain biologic inflammation, poor quality of life but not with structural damage <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.6006
ECHOCARDIOGRAPHIC MARKERS OF LEFT ATRIAL FIBROSIS ASSOCIATED WITH THE SEVERITY OF ATRIAL FIBRILLATION
Authors: Melissa Leung, Rachid Abou, Philippe Van Rosendael, Suzanne Van Wijngaarden, Madelien Regeer, Tomaz Podlesnikar, Nina Ajmone Marsan, Victoria Delgado, Jeroen Bax
Journal: Journal of the American College of Cardiology (2016)
P12.12 * FOLLOWING MOTOR TRACTS IN BRAIN TUMOR SURGERY: NEUROPHYSIOLOGICAL STRATEGIES AND CLINICAL IMPACT
Authors: M. Riva, E. Fava, A. Comi, L. Fornia, V. Ferpozzi, F. Raneri, A. Castellano, A. Falini, L. Bello
Journal: Neuro-Oncology (2014)

Resection of Cortical-Spinal-Tract (CST) tumors requires the intraoperative identification of cortical-subcortical essential motor-sites. Neurophysiological strategies for motor mapping and monitoring available are: Low/High-Frequency, LF/HF, delivered with monopolar-bipolar probes, MEP monitoring. Tailoring them to the clinical status and tumor characteristics may improve motor-site identification, extent-of-resection (EOR), patient safety. We report our experience on the tailored use of these neurophysiological strategies on a group of 479 CST tumors patients, comparing neurophysiological and functional results with a control comparable group of 112 patients in which only LF was available. Patient clinical characteristics, MR (including DTI) tumors features were available. Efficacy (rate of cortical-subcortical motor-site identification), immediate/permanent deficits, EOR were evaluated. LF by bipolar probe identified motor sites in patients with short seizure history, sharp border tumors, displaced and slightly infiltrated CST (DTI). Total EOR was 84.1%, immediate and permanent deficits were 59.1% and 0%. HF by monopolar probe was needed in patients with long seizure history, previous treatments, highly infiltrated CST. In these patients LF didn't detect motor responses and induced seizures, becoming effective only at the end of surgery in 72% of patients. Total EOR was 59.9%, immediate/permanent deficits were 63%/1.7%. In 3.5% of tumors inside the CST, HF by monopolar and bipolar probes was needed for fiber identification. Total EOR was 60% with no permanent deficits. In the latter groups of patients, LF alone showed a lower efficacy, higher permanent deficits, lower EOR. By integrating the choice of the probe and the stimulating protocol with patient clinical history and tumor characteristics, the best “probe-frequency match” to be applied in different clinical conditions was identified. This integrative approach allows increasing the extent of resection and patient functional integrity, and strongly expanding the number of patients who benefit from surgery The integration of stimulation modalities with clinical context enhances resection extent and safety, and largely expands the population of patients who benefit from surgical treatment.